Vaxcyte, Inc. $PCVX Shares Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 10.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 293,134 shares of the company’s stock after purchasing an additional 28,430 shares during the quarter. Raymond James Financial Inc. owned approximately 0.23% of Vaxcyte worth $11,069,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Parallel Advisors LLC boosted its position in shares of Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock valued at $61,000 after purchasing an additional 1,071 shares during the period. IFP Advisors Inc boosted its position in shares of Vaxcyte by 376.4% in the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after purchasing an additional 1,306 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Vaxcyte by 10.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company’s stock valued at $112,000 after purchasing an additional 293 shares during the period. J.Safra Asset Management Corp boosted its position in shares of Vaxcyte by 65.8% in the 1st quarter. J.Safra Asset Management Corp now owns 3,161 shares of the company’s stock valued at $119,000 after purchasing an additional 1,254 shares during the period. Finally, GF Fund Management CO. LTD. boosted its position in shares of Vaxcyte by 22.0% in the 1st quarter. GF Fund Management CO. LTD. now owns 3,192 shares of the company’s stock valued at $121,000 after purchasing an additional 575 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cowen reissued a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $136.50.

Vaxcyte Stock Up 0.1%

PCVX opened at $30.79 on Friday. The business has a 50 day moving average price of $33.34 and a two-hundred day moving average price of $42.46. The company has a market cap of $4.00 billion, a PE ratio of -7.49 and a beta of 1.21. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the previous year, the firm earned ($1.10) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.